Associated Papers
Pathogenic germline variants in Chinese pancreatic adenocarcinoma patients.
Yin X et al.
Nature Communications, 2025
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
Genetic Variants in the Mitochondrial Thymidylate Biosynthesis Pathway Increase Colorectal Cancer Risk.
Arrait EM et al.
Current Oncology (toronto, Ont.), 2023
Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African Americans.
Telisnor G et al.
Journal of the National Medical Association, 2023
Role of Genetic Polymorphisms in Drug-Metabolizing Enzyme-Mediated Toxicity and Pharmacokinetic Resistance to Anti-Cancer Agents: A Review on the Pharmacogenomics Aspect.
Narendra G et al.
Clinical Pharmacokinetics, 2022
Comparison of genetic susceptibility to lung adenocarcinoma and squamous cell carcinoma in Japanese patients using a novel panel for cancer-related drug-metabolizing enzyme genes.
Ohnami S et al.
Scientific Reports, 2022
Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives.
Pinto-Merino Á et al.
Pharmaceutics, 2022
Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.
Kim B et al.
Translational and Clinical Pharmacology, 2021
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel.
Vivaldi C et al.
The Pharmacogenomics Journal, 2021
Whole-Exome Profiling of NSCLC Among African Americans.
Arauz RF et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2020
Associations of cytosine deaminase gene polymorphisms with effectiveness of gemcitabine/cisplatin chemotherapy in patients of Xinjiang Uyghur and Han nationality with non-small cell lung cancer.
Li J et al.
The International Journal of Biological Markers, 2019
Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours.
Cohen R et al.
British Journal of Clinical Pharmacology, 2019
Pharmacogenetics of hepatocellular carcinoma and cholangiocarcinoma.
Alonso-Peña M et al.
Cancer Drug Resistance (alhambra, Calif.), 2019
Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target.
Dufva O et al.
Nature Communications, 2018
Severe acute toxicity following gemcitabine administration: A report of four cases with cytidine deaminase polymorphisms evaluation.
Hryciuk B et al.
Oncology Letters, 2018
Genotypes Affecting the Pharmacokinetics of Anticancer Drugs.
Bertholee D et al.
Clinical Pharmacokinetics, 2017
Whole exome sequencing detects variants of genes that mediate response to anticancer drugs.
Ohnami S et al.
The Journal of Toxicological Sciences, 2017
The role of pharmacogenetics in capecitabine efficacy and toxicity.
Lam SW et al.
Cancer Treatment Reviews, 2016
Impact of Polymorphic Variations of Gemcitabine Metabolism, DNA Damage Repair, and Drug-Resistance Genes on the Effect of High-Dose Chemotherapy for Relapsed or Refractory Lymphoid Malignancies.
Shinozuka K et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation, 2016
Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.
Frank TS et al.
Cancer Letters, 2015
Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs.
Serdjebi C et al.
Expert Opinion on Drug Metabolism & Toxicology, 2015
Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy.
Ding X et al.
Gene, 2015
FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients.
Serdjebi C et al.
Plos One, 2015
Cytidine Deaminase as a Molecular Predictor of Gemcitabine Response in Patients with Biliary Tract Cancer.
Yoon KA et al.
Oncology, 2015
Association of xeroderma pigmentosum group D (Asp312Asn, Lys751Gln) and cytidine deaminase (Lys27Gln, Ala70Thr) polymorphisms with outcome in Chinese non-small cell lung cancer patients treated with cisplatin-gemcitabine.
Zhou M et al.
Genetics and Molecular Research : Gmr, 2014
Human cytidine deaminase: a biochemical characterization of its naturally occurring variants.
Micozzi D et al.
International Journal of Biological Macromolecules, 2014
Determination of common genetic variants in cytidine deaminase (CDA) gene in Indian ethnic population.
Iyer SN et al.
Gene, 2013
Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase.
Baker JA et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2013
Genotype frequencies of drug-metabolizing enzymes responsible for purine and pyrimidine antagonists in a healthy Asian-Indian population.
Iyer SN et al.
Biochemical Genetics, 2012
High incidence of severe neutropenia after gemcitabine-based chemotherapy in Chinese cancer patients with CDA 79A>C mutation.
Xu J et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry, 2012
Genetic polymorphisms of XPD and CDA and lung cancer risk.
Zhou M et al.
Oncology Letters, 2012
A genome-wide association study identifies four genetic markers for hematological toxicities in cancer patients receiving gemcitabine therapy.
Kiyotani K et al.
Pharmacogenetics and Genomics, 2012
Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine.
Joerger M et al.
Cancer Chemotherapy and Pharmacology, 2012
The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma.
Erčulj N et al.
Pharmacogenetics and Genomics, 2012
Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients.
Ludovini V et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2011
Rapid allele-specific PCR method for CDA 79A>C (K27Q) genotyping: a useful pharmacogenetic tool and world-wide polymorphism distribution.
Carpi FM et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry, 2011
Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs.
Sai K et al.
Expert Opinion on Drug Metabolism & Toxicology, 2011
A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.
Caronia D et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2011
Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours.
Gusella M et al.
British Journal of Clinical Pharmacology, 2011
The pharmacological advantage of prolonged dose rate gemcitabine is restricted to patients with variant alleles of cytidine deaminase c.79A>C.
Metharom E et al.
Asia-pacific Journal of Clinical Oncology, 2011
[Pharmacogenomic research for avoiding adverse reactions by anti-cancer drugs].
Saito Y
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan, 2011
Influence of polymorphisms on EGFR targeted therapy in non-small-cell lung cancer.
Giovannetti E et al.
Frontiers in Bioscience (landmark Edition), 2011
Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.
Deenen MJ et al.
The Oncologist, 2011
Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer.
Tanaka M et al.
Cancer, 2010
Letter to the editor: pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism.
Mercier C et al.
European Journal of Clinical Pharmacology, 2010
Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.
Sugiyama E et al.
Clinical Pharmacokinetics, 2010
Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism.
Maring JG et al.
European Journal of Clinical Pharmacology, 2010